ProMIS Neurosciences (PMN) AI Stock Analysis

• Market Cap: $25.17M
• Dividend Yield: N/A
• Average Volume (3M): 45.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: 89.75%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 32,689,190
• 10 Day Avg. Volume: 47,416
• 30 Day Avg. Volume: 45,559
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 809.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

ProMIS Neurosciences faces substantial financial and operational challenges, notably its lack of revenue and reliance on external funding. Technical indicators suggest bearish momentum, and valuation metrics reflect development-stage financials. However, the company's strategic focus on neurodegenerative diseases and recent trial initiation provide a positive outlook for future prospects, slightly offsetting current risks.

Positive Factors

Dosing Efficiency

The half-life of PMN310 was determined to be approximately 25 days, which supports once-per-month dosing, enhancing patient convenience and compliance.

Financial Position

The recently completed PIPE financing provides an initial upfront funding of $30.3M with the potential for an additional $92.4M, boosting the company's financial resources.

Safety and Tolerability

PMN310 demonstrated a favorable safety and tolerability profile with no treatment-emergent serious adverse events observed.

Negative Factors

Cash Reserves

The company finished with only $1.0M in cash and cash equivalents, a concern for ongoing operational expenses.

Complexity in Targeting TDP-43

Targeting TDP-43 involves complex dosing determinations due to its essential role in cells and its involvement in multiple conditions, posing potential challenges in treatment development.

ProMIS Neurosciences Business Overview & Revenue Model

Company Description

ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of therapeutic solutions targeting neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company's core products include proprietary monoclonal antibodies designed to selectively target toxic forms of misfolded proteins implicated in these diseases. ProMIS utilizes its innovative discovery platform to identify and develop novel therapeutics aimed at modifying disease progression and improving patient outcomes.

How the Company Makes Money

ProMIS Neurosciences generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve licensing agreements, where ProMIS grants rights to its proprietary technologies and therapeutic candidates in exchange for upfront payments, milestone payments, and potential royalties on sales. Additionally, the company may receive funding from government grants and research institutions to support its development programs. ProMIS's earnings are significantly influenced by the success of its clinical trials, the advancement of its drug candidates through regulatory approvals, and the establishment of strategic partnerships to enhance its research and development efforts.

ProMIS Neurosciences Financial Statement Overview

Summary

ProMIS Neurosciences demonstrates significant financial challenges, with no revenue generation and consistent net losses. The balance sheet is stable with no debt, but lacks significant equity for growth. Cash flows highlight dependence on external financing, indicating potential liquidity risks if funding sources diminish.

Income Statement

The company has reported zero revenue over the periods, indicating no sales. The net income is negative, reflecting ongoing losses. The EBITDA margin is positive in TTM (Trailing-Twelve-Months), suggesting some improvement in operational expenses, but EBIT remains negative, showcasing profitability challenges.

Balance Sheet

The balance sheet shows no debt, which is a positive indicator of leverage stability. However, the equity is limited, restricting growth potential. The equity ratio is reasonable at 29.7% in TTM, suggesting a modest level of financial stability but limited resources for expansion.

Cash Flow

Operating cash flow is negative, indicating cash outflows from core operations. Free cash flow is also negative, suggesting that the company is not generating cash for reinvestment or dividends. The financing cash flows are substantial, indicating reliance on external funding for operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	―	―	―
	Gross Profit
0.00	-10.44M	-21.78M	―	―	―
	EBIT
-14.70M	-18.90M	-23.38M	―	―	―
	EBITDA
2.98M	-17.81M	-29.88M	-9.33M	―	―
	Net Income Common Stockholders
-563.35K	-17.51M	-12.74M	―	―	―
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.43M	16.75M	8.01M	21.48M	1.11M	1.70M
	Total Assets
2.97M	18.04M	9.38M	22.44M	1.38M	2.07M
	Total Debt
0.00	0.00	0.00	4.94M	0.00	0.00
	Net Debt
-2.39M	-16.69M	-7.96M	-16.49M	-1.03M	-1.66M
	Total Liabilities
1.81M	13.07M	8.68M	15.28M	2.40M	1.68M
	Stockholders Equity
1.16M	4.97M	―	7.16M	-1.02M	398.12K
Cash Flow		Free Cash Flow
-22.01M	-14.37M	-17.04M	―	―	―
	Operating Cash Flow
-22.01M	-14.37M	-17.03M	―	―	―
	Investing Cash Flow
0.00	―	-1.98K	94.33K	―	―
	Financing Cash Flow
26.66M	23.52M	6.49M	25.20M	3.01M	4.10M

ProMIS Neurosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 0.89, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMN.

ProMIS Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$78.51B	19.43	15.95%	0.12%	8.27%	10.35%
AMGN	75 Outperform	$171.31B	43.30	67.55%	2.79%	18.64%	-39.39%
BIIB	69 Neutral	$21.03B	12.85	10.36%	―	-1.60%	39.71%
LLY	65 Neutral	$781.20B	70.84	84.84%	0.65%	32.00%	102.18%
VRTX	64 Neutral	$128.40B	―	-3.15%	―	11.64%	-114.72%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
PMN	35 Underperform	$25.17M	―	-8.03%	―	―	89.75%

ProMIS Neurosciences Corporate Events

ProMIS Neurosciences Highlights Neurodegenerative Disease Focus

On January 27, 2025, ProMIS Neurosciences Inc. announced an updated corporate presentation highlighting its focus on addressing unmet needs in neurodegenerative diseases. The company has a diverse pipeline, including the lead program PMN310 for Alzheimer’s, which is undergoing a Phase 1b clinical trial. The company emphasizes its potential to develop safer, more effective therapies by targeting specific misfolded proteins, supported by a seasoned leadership team and significant funding secured in July 2024.

ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s

ProMIS Neurosciences announced the initiation of its Phase 1b clinical trial for PMN310, a therapeutic candidate aimed at treating Alzheimer’s disease by selectively targeting toxic amyloid-beta oligomers. The trial will assess safety, tolerability, and efficacy over 12 months in 100 patients, with the potential for PMN310 to offer a differentiated product profile by reducing the risk of amyloid-related imaging abnormalities. The company aims to address the unmet needs in Alzheimer’s treatment through this trial, which collaborates with leading U.S. treatment centers.